Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
SF-36 Health Survey Update
4.419
Zitationen
1
Autoren
2000
Jahr
Abstract
From QualityMetric, Inc.; Lincoln, Rhode Island; and the Health Assessment Lab; Tufts Medical School, and Harvard School of Public Health, Boston, Massachusetts. Address reprint requests to John E. Ware, Jr., PhD QualityMetric, Inc. 640 George Washington Highway Lincoln, RI 02865 E-mail: [email protected] Development and validation of the SF-36 Health Survey was supported by a grant from the Henry J. Kaiser Family Foundation to The Health Institute, New England Medical Center (J. E. Ware, Jr., Principal Investigator). Development of the SF-36 PCS and MCS summary measures was supported by unrestricted research grants for the International Quality of Life Assessment (IQOLA) Project for the Glaxo Research Institute, Research Triangle Park, NC and Schering-Plough Corp., Kenilworth, NJ (J. E. Ware, Jr., Principal Investigator). The IQOLA Project is sponsored by unrestricted research grants from GlaxoWellcome Inc., Research Triangle Park, NC, and Schering-Plough Corp., Kenilworth, NJ. Associate sponsors include Astra, Parke-Davis, Pharmacia & Upjohn, Proctor & Gamble Pharmaceuticals, Searle, Solvay Duphar B.V., and Synthelabo. Additional support has also been provided by more than 40 other pharmaceutical companies.
Ähnliche Arbeiten
Meta-analysis in clinical trials
1986 · 38.718 Zit.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 · 37.510 Zit.
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
2018 · 36.968 Zit.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 · 33.417 Zit.
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · 28.245 Zit.